The stock market experienced slight losses yesterday, with consumer discretionary stocks being the day’s duds, posting a 1% decline. The S&P 500 Index fell 0.2%, the Dow Jones Industrial Average declined 0.1% and the Nasdaq Composite slipped 0.4%.
Here’s how they did:
Cal-Maine Foods Inc (CALM)
Cal-Maine Foods had decent quarterly data in its most recent period.
Over the course of the three-month period, earnings came in at 48 cents per share. Analysts were calling for earnings amounting to the same figure over the quarter.
As far as net sales go, Cal-Maine Foods managed to rake in $253.50 million, which was weaker than the $262.83 million that the consensus estimate called for.
However, the company posted a strong return on equity of 15.81%, while its net margin came in at 9.23%. Revenue was down 53% year-over-year, as the egg industry was to blame for the tough quarter.
There was a reduced demand for egg products over the three months.
The stock has an average consensus estimate of a “hold,” with a price target of $38.20.
CALM stock wafted up 1.31% after the bell yesterday.
Cintas Corporation (CTAS)
Cintas Corporation had a disappointing second quarter.
Yesterday, the company reported its fiscal second-quarter results which failed to meet expectations. Earnings came in at $140.4 million over, or about $1.29 per share.
On an adjusted basis, this figure was down to $1.15 per share. Analysts were calling for earnings of $1.16 per share, based on an average estimate of nine analysts.
Revenue managed to be higher than expected at $1.3 billion for the three-month period. Analysts were projecting revenue of $1.29 billion, according to six analysts surveyed by Zacks.
Full-year earnings are now slated to come in at around $4.51 to $4.59 per share, while revenue will be in the range of $5.18 billion to $5.23 billion.
CTAS shares lost 3.8% after hours Thursday.
OHR Pharmaceutical (OHRP)
OHR Pharmaceutical had a strong end of the year that helped shares rise higher.
The company revealed that its fiscal year 2016 was marked by progress in a number of drugs, including eye drop formulation Squalamine, as well as several other medications.
Overall, the year resulted in losses of $25.8 million, or 82 cents per share. The figure was wider than the 54 cents lost in the previous year.
OHR Pharmaceutical had cash and cash equivalents of $12.5 million by year’s end, which was about half of what it had in the previous year.
However, the company made progress in testing a number of drugs that have been costly. OHR Pharmaceutical expects to reap the rewards in the coming year, pending Food and Drug Administration approval.
OHRP stock soared 5.7% after the ring of the bell Thursday.
As of this writing, Karl Utermohlen did not hold a position in any of the aforementioned securities.